RUNX1 and acute myeloid leukemia: In summary, the identified M23, M27, and M10 together with 7.44 might serve as lead structures for further optimization of binding affinity, bioavailability, and anti-leukemic effects of compounds inhibiting RUNX1/ETO oncogenic function in t(8;21) acute myeloid leukemia.